エトポシド 価格 もっと(40)

メーカー	製品番號	製品説明	CAS番號	包裝	価格	更新時間	購入
富士フイルム和光純薬株式會社(wako)	W01USP1268852	エトポシド Resolution Mixture (10 mg) Etoposide Resolution Mixture (10 mg)	33419-42-0	10mg	￥312900	2024-03-01	購入
富士フイルム和光純薬株式會社(wako)	W01USP1268808	エトポシド Etoposide	33419-42-0	300mg	￥91400	2024-03-01	購入
富士フイルム和光純薬株式會社(wako)	W01MPB02193918	エトポシド Etoposide	33419-42-0	250mg	￥44400	2024-03-01	購入
富士フイルム和光純薬株式會社(wako)	W01COBQA-7668	エトポシド Etoposide	33419-42-0	1g	￥17500	2024-03-01	購入
富士フイルム和光純薬株式會社(wako)	W01COBQA-7668	エトポシド Etoposide	33419-42-0	10g	￥108000	2023-06-01	購入

エトポシド MSDS

Etoposide

エトポシド 化學(xué)特性,用途語,生産方法

外観

白色?わずかにうすい褐色, 結(jié)晶性粉末?粉末

溶解性

メタノールにやや溶けにくく、エタノールに溶けにくく、水に極めて溶けにくい。

用途

抗腫瘍薬(リンパ腫、ホジキンリンパ腫、精巣癌、肺癌(特に小細(xì)胞性)、急性白血病)

用途

ポドフィリン系化合物です。 トポイソメラーゼⅡ阻害剤として作用しま す。

効能

抗悪性腫瘍薬, トポイソメラーゼII阻害薬

商品名

ベプシド (ブリストル?マイヤーズスクイブ); ベプシド (ブリストル?マイヤーズスクイブ); ラステット (日本化薬); ラステット (日本化薬)

説明

Etoposide is a plant alkaloid and an inhibitor of topoisomerase II (IC₅₀ = 60.3 μM). It inhibits proliferation of a variety of adenocarcinoma cells (IC₅₀s = 0.005-12,200 μM) and human umbilical vein endothelial (HUVEC) cells (IC₅₀ = 0.249 μM). It reduces tumor growth in an Ma human embryonal carcinoma mouse xenograft model when administered at a dose of 25 mg/kg, an effect that is enhanced by concomitant administration of the immunosuppressant cyclosporin A . Etoposide also inhibits nuclear receptor coactivator 3 (IC₅₀ = 2.48 μM). Formulations containing etoposide have been used in combination therapy in the treatment of cancer.

化學(xué)的特性

White or almost white, crystalline powder, slightly hygroscopic

使用

Etoposide is used for germinogenic tumors, ovarian, stomach, and lung cancer, Hodgkin’s disease, and non-Hodgkin’s lymphoma for both monotherapy and in combination therapy.

適応癥

Etoposide (VePesid) is a semisynthetic derivative of podophyllotoxin that is produced in the roots of the American mandrake, or May apple. Unlike podophyllotoxin and vinca alkaloids, etoposide does not bind to microtubules. It forms a complex with the enzyme topoisomerase II, which results in a single-strand breakage of DNA. It is most lethal to cells in the S- and G2-phases of the cell cycle. Drug resistance to etoposide is thought to be caused by decreased cellular drug accumulation.
Etoposide is most useful against testicular and ovarian germ cell cancers, lymphomas, small cell lung cancers, and acute myelogenous and lymphoblastic leukemia.Toxicities include mild nausea, alopecia, allergic reaction, phlebitis at the injection site, and bone marrow toxicity.

臨床応用

Etoposide is utilized in the treatment of small cell lung cancer and in combination with other agents in refractory testicular cancer.

安全性プロファイル

Poison by ingestion, intraperitoneal, intravenous, and subcutaneous routes. An experimental teratogen. Human systemic effects by ingestion and inhalation: agranulocytosis, aplastic anemia, and other changes in bone marrow. Experimental reproductive effects. Human mutation data reported. When heated to decomposition it emits acrid smoke and fumes.

代謝

The drug is more than 96% protein bound, undergoes biphasic elimination, and has a terminal half-life of 4 to 11 hours. Approximately 35 to 45% of a dose is eliminated via the kidneys, with less than 6% excreted in feces. The drug should be used with caution in patients with renal or liver disease.

參考文獻(xiàn)

Hande, K. R. "Etoposide: four decades of development of a topoisomerase II inhibitor." European Journal of Cancer34.10(1998):1514.
Noda, K, et al. "Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer." New England Journal of Medicine 346.2(2002):85-91.

エトポシド 上流と下流の製品情報

原材料

準(zhǔn)備製品

エトポシド 生産企業(yè)

名前	電話番號	電子メール	國籍	製品カタログ	優(yōu)位度
Henan Bao Enluo International TradeCo.，LTD	+86-17331933971	deasea125996@gmail.com	China	2472	58
Shaanxi TNJONE Pharmaceutical Co., Ltd		sarah@tnjone.com	China	1143	58
Beijing Cooperate Pharmaceutical Co.,Ltd	010-60279497	sales01@cooperate-pharm.com	CHINA	1803	55
Henan Tianfu Chemical Co.,Ltd.	+86-0371-55170693 +86-19937530512	info@tianfuchem.com	China	21585	55
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	ivan@atkchemical.com	China	33024	60
Shanghai Zheyan Biotech Co., Ltd.	18017610038	zheyansh@163.com	CHINA	3619	58
career henan chemical co	+86-0371-86658258	sales@coreychem.com	China	29812	58
Chengdu GLP biotechnology Co Ltd	028-87075086 13350802083	scglp@glp-china.com	CHINA	1824	58
TianYuan Pharmaceutical CO.,LTD	+86-755-23284190 13684996853	sales@tianpharm.com	CHINA	304	58
Biochempartner	0086-13720134139	candy@biochempartner.com	CHINA	965	58

33419-42-0(エトポシド)キーワード:

---

• 33419-42-0
• (-)-Etoposide, (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside
• EtoposideETOPOSIDE
  CAS:33419-42-0
  MES-012
• BMY-40481, Etoposide 4'-Dihydrogenphosphate, VP-16-213
• GAL4 [(1-147) + VP16 (411-490)] from Saccharomyces cerevisiae human herpesvirus 2
• Etoposide, >=98%
• (5R,5aR,8aR,9S)-9-[[4,6-O-(1R)-Ethylidene-β-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one
• (5R,5AR,8aR,9S)-9-(((2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methylhexahydropyrano[3,2-d][1,3]dio
• VP-16-213
• epipodophyllotoxin,4’-demethyl-,4,6-o-ethylidene-beta-d-glucopyranoside
• epipodophyllotoxin,4’-demethyl-,9-(4,6-o-ethylidene-beta-d-glucopyranoside)
• lastet
• nk171
• nsc141540
• nsc-141540
• 4'-DEMETHYLEPIPODOPHYLLOTOXIN 9-(4,6-O-ETHYLIDENE-BETA-D-GLUCOPYRANOSIDE)
• 4-demethylepipodophyllotoxin-beta-d-ethylideneglucoside
• Etoposide4-O--D-Galactopyranoside
• Furo3,4:6,7naphtho2,3-d-1,3-dioxol-6(5aH)-one, 9-4,6-O-(1R)-ethylidene-.beta.-D-glucopyranosyloxy-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R,5aR,8aR,9S)-
• 4'-demethylepipodophyllotoxin 9-(4,6-o-ethylidene-β-d-glucopyranoside)
• Etoposide(α-tipe)
• 4'-Demethyl-1-O-[4,6-O-(ethylidene)-β-D-glucopyranosyl]epipodophyllotoxin
• 4'-Demethylepipodophyllotoxin ethylidene-β-D-glucoside
• Epipodophyllotoxin VP 16213
• Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-β-D-glucopyranoside (8CI)
• Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 9-[(4,6-O-ethylidene-β-D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, [5R-[5α,5aβ,8aα,9β(R*)]]-
• Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 9-[[4,6-O-(1R)-ethylidene-β-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R,5aR,8aR,9S)-
• trans-Etoposide
• VP 16 (pharmaceutical)
• VP 16-123
• Zuyeyidal
• エトポシド (約5%エタノール含む)
• エトポシド
• (-)-エトポシド
• 4'-デメチルエピポドフィロトキシン4,6-O-エチリデン-β-D-グルコピラノシド
• (5R)-9α-[[4-O,6-O-[(R)-エチリデン]-β-D-グルコピラノシル]オキシ]-5,8,8aβ,9-テトラヒドロ-5β-(4-ヒドロキシ-3,5-ジメトキシフェニル)フロ[3',4':6,7]ナフト[2,3-d]-1,3-ジオキソール-6(5aαH)-オン
• ラステット
• (5R,5aα)-9α-[4-O,6-O-[(R)-エチリデン]-β-D-グルコピラノシルオキシ]-5,8,8aβ,9-テトラヒドロ-5β-(4-ヒドロキシ-3,5-ジメトキシフェニル)フロ[3',4':6,7]ナフト[2,3-d]-1,3-ジオキソール-6(5aH)-オン
• (5R)-5,8,8aβ,9-テトラヒドロ-9α-[4-O,6-O-[(R)-エチリデン]-β-D-グルコピラノシルオキシ]-5β-(4-ヒドロキシ-3,5-ジメトキシフェニル)フロ[3',4':6,7]ナフト[2,3-d]-1,3-ジオキソール-6(5aαH)-オン
• ベペシド
• (5R)-9α-[4-O,6-O-[(R)-エチリデン]-β-D-グルコピラノシルオキシ]-5,8,8aβ,9-テトラヒドロ-5β-(4-ヒドロキシ-3,5-ジメトキシフェニル)フロ[3',4':6,7]ナフト[2,3-d]-1,3-ジオキソール-6(5aαH)-オン
• ベプシド
• ラステットS
• (5R,5aα,9S)-9-[[4-O,6-O-[(R)-エチリデン]-β-D-グルコピラノシル]オキシ]-5,8,8aβ,9-テトラヒドロ-5-(4-ヒドロキシ-3,5-ジメトキシフェニル)フロ[3',4':6,7]ナフト[2,3-d]-1,3-ジオキソール-6(5aH)-オン
• 4'-デメチルエピポドフィロトキシン9-(4,6-O-エチリデン-β-D-グルコピラノシド)
• エトポシド混合物
• エトポシド (JP17)
• 4′-デメチルエピポドフィロトキシン4,6-O-エチリデン-β-D-グルコピラノシド
• (5R)-9α-[[4-O,6-O-[(R)-エチリデン]-β-D-グルコピラノシル]オキシ]-5,8,8aβ,9-テトラヒドロ-5β-(4-ヒドロキシ-3,5-ジメトキシフェニル)フロ[3′,4′:6,7]ナフト[2,3-d]-1,3-ジオキソール-6(5aαH)-オン
• (10R,11R,15R,16S)-16-{[(2R,4aR,6R,7R,8R,8aS)-7,8-ジヒドロキシ-2-メチル-ヘキサヒドロ-2H-ピラノ[3,2-d][1,3]ジオキシン-6-イル]オキシ}-10-(4-ヒドロキシ-3,5-ジメトキシフェニル)-4,6,13-トリオキサテトラシクロ[7.7.0.03,7.011,15]ヘキサデカ-1,3(7),8-トリエン-12-オン
• (5R,5aR,8aR,9S)-9-[4-O,6-O-[(R)-エチリデン]-β-D-グルコピラノシルオキシ]-5,8,8a,9-テトラヒドロ-5-(4-ヒドロキシ-3,5-ジメトキシフェニル)フロ[3′,4′:6,7]ナフト[2,3-d]-1,3-ジオキソール-6(5aH)-オン
• (5R,5aα)-9α-[4-O,6-O-[(R)-エチリデン]-β-D-グルコピラノシルオキシ]-5,8,8aβ,9-テトラヒドロ-5β-(4-ヒドロキシ-3,5-ジメトキシフェニル)フロ[3′,4′:6,7]ナフト[2,3-d]-1,3-ジオキソール-6(5aH)-オン
• (5R,5aα,9S)-9-[[4-O,6-O-[(R)-エチリデン]-β-D-グルコピラノシル]オキシ]-5,8,8aβ,9-テトラヒドロ-5-(4-ヒドロキシ-3,5-ジメトキシフェニル)フロ[3′,4′:6,7]ナフト[2,3-d]-1,3-ジオキソール-6(5aH)-オン
• (5R)-9α-[4-O,6-O-[(R)-エチリデン]-β-D-グルコピラノシルオキシ]-5,8,8aβ,9-テトラヒドロ-5β-(4-ヒドロキシ-3,5-ジメトキシフェニル)フロ[3′,4′:6,7]ナフト[2,3-d]-1,3-ジオキソール-6(5aαH)-オン
• (5R)-5,8,8aβ,9-テトラヒドロ-9α-[4-O,6-O-[(R)-エチリデン]-β-D-グルコピラノシルオキシ]-5β-(4-ヒドロキシ-3,5-ジメトキシフェニル)フロ[3′,4′:6,7]ナフト[2,3-d]-1,3-ジオキソール-6(5aαH)-オン
• グルコース
• 生化學(xué)
• 試験研究用抗腫瘍剤
• 糖
• 阻害剤
• 抗腫瘍薬